The Art Of Cure – FDA Warning Letter, Apr 13, 2020
On April 15, 2020, the FDA and FTC issued a Warning Letter to The Art of Cure regarding unapproved and misbranded homeopathic drug products marketed for COVID-19. The agencies reviewed the company's websites, theartofcure.net and facebook.com/TheArtOfCure/, on April 1 and April 13, 2020.
The FDA found that the products are unapproved new drugs, violating section 505(a) of the FD&C Act (21 U.S.C. § 355(a)), and misbranded drugs under section 502 (21 U.S.C. § 352). The introduction of these products into interstate commerce is prohibited by sections 301(a) and (d) (21 U.S.C. § 331(a) and (d)). The FTC determined that claims of preventing, treating, or curing COVID-19 lacked competent and reliable scientific evidence, violating the FTC Act (15 U.S.C. 41 et seq.).
The letter demands immediate cessation of sales of these unapproved products for COVID-19. The company must email COVID-19-Task-Force-CDER@fda.hhs.gov within 48 hours, detailing corrective actions, steps to prevent recurrence, and supporting documentation. Failure
ID · ffe06466-99d3-42bc-82d8-8a3cd052c75f
Full citation text and observation details available on the Dashboard.
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.